Your browser doesn't support javascript.
loading
Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu, Shugui; Wu, Shanlian; Liao, Xiaohong; Zhou, Chaoming; Qiu, Feng; Wang, Chen; Zhong, Wenjuan.
Afiliação
  • Wu S; Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
  • Wu S; Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.
  • Liao X; Department of Pathology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.
  • Zhou C; Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
  • Qiu F; Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.
  • Wang C; Department of Oncology, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, China.
  • Zhong W; Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.
Front Immunol ; 14: 1274937, 2023.
Article em En | MEDLINE | ID: mdl-37936698
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares Limite: Aged / Female / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares Limite: Aged / Female / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China